Targeting KRAS oncogene in colon cancer cells with 7-carboxylate Indolo[3,2-b] quinoline tri-alkylamine derivatives

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Brito, Hugo ^a   Martins, Ana Cláudia ^a   Lavrado, João ^a   Mendes, Eduarda ^a   Francisco, Ana Paula ^a   Santos, Sofia A ^a,b   Ohnmacht, Stephan A ^c   Kim, Nam Soon ^d   Rodrigues, Cecília M P ^a   Moreira, Rui ^a   Neidle, Stephen ^c   Borralho, Pedro M ^a   Paulo, Alexandra ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

7 CARBOXYLATE INDOLO[3,2 B]QUINOLINE TRI ALKYLAMINE DERIVATIVE; ALIPHATIC AMINE; ANTINEOPLASTIC AGENT; FLUOROURACIL; INDOLOQUINOLINE DERIVATIVE; MESSENGER RNA; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG; GUANINE QUADRUPLEX; QUINOLINE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; COLON CANCER; CONTROLLED STUDY; DNA STRUCTURE; DOWN REGULATION; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IC50; ONCOGENE K RAS; PROMOTER REGION; STEADY STATE; CELL PROLIFERATION; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; ONCOGENE RAS; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; G-QUADRUPLEXES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HCT116 CELLS; HEK293 CELLS; HUMANS; PROMOTER REGIONS, GENETIC; QUINOLINES;

EID: 84934910595     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126891     Document Type: Article

References (36)

1. Dunn EF, lida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene. 2011; 30: 561-574. doi: 10.1038/onc.2010.430 PMID: 20956938
2. Krens LL, Baas JM, Gelderblom H, Guchelaar HJ. Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discovery Today. 2010; 15: 502-516. doi: 10.1016/j.drudis.2010.05.012 PMID: 20594936
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-386. doi: 10.1002/ijc.29210 PMID: 25220842
4. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 2005; 14 Suppl 1: 35-48. PMID: 16103712
5. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission Possible? Nat Rev Drug Discov. 2014; 13: 828-851. doi: 10.1038/nrd4389 PMID: 25323927
6. Tsujii M. Search for Novel Target Molecules for the Effective Treatment or Prevention of Colorectal Cancer. Digestion. 2012; 85: 99-102. doi: 10.1159/000334678 PMID: 22269287
7. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. Febs J. 2009; 276: 6689-6700. doi: 10.1111/j.1742-4658.2009.07383.x PMID: 19843160
8. Borralho PM, Simoes AES, Gomes SE, Lima RT, Carvalho T, Ferreira DM, et al. miR-143 Overexpression Impairs Growth of Human Colon Carcinoma Xenografts in Mice with Induction of Apoptosis and Inhibition of Proliferation. Plos One. 2011; 6(8):e23787. doi: 10.1371/journal.pone.0023787 PMID: 21901135
9. Capucha V, Mendes E, Francisco AP, Perry MJ. Development of triazene prodrugs for ADEPT strategy: New insights into drug delivery system based on carboxypeptidase G2 activation. Bioorg Med Chem Lett. 2012; 22: 6903-6908. doi: 10.1016/j.bmcl.2012.09.029 PMID: 23041157
10. Monteiro AS, Almeida J, Cabral G, Severino P, Videira PA, Sousa A, et al. Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines. Eur J Med Chem. 2013; 70: 1-9. doi: 10.1016/j.ejmech.2013.09.040 PMID: 24125877
11. Perry MJ, Mendes E, Simplicio AL, Coelho A, Soares RV, Iley J,et al. Dopamine- and tyramine-based derivatives of triazenes: Activation by tyrosinase and implications for prodrug design. Eur J Med Chem. 2009; 44: 3228-3234. doi: 10.1016/j.ejmech.2009.03.025 PMID: 19386398
12. Cogoi S, Xodo LE. G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription. Nucleic Acids Res. 2006; 34: 2536-2549. PMID: 16687659
13. Cogoi S, Paramasivam M, Spolaore B, Xodo LE. Structural polymorphism within a regulatory element of the human KRAS promoter: formation of G4-DNA recognized by nuclear proteins. Nucleic Acids Res. 2008; 36: 3765-3780. doi: 10.1093/nar/gkn120 PMID: 18490377
14. Burge S, Parkinson GN, Hazel P, Todd AK, Neidle S. Quadruplex DNA: sequence, topology and structure. Nucleic Acids Res. 2006; 34: 5402-5415. PMID: 17012276
15. Neidle S. Human telomeric G-quadruplex: The current status of telomeric G-quadruplexes as therapeutic targets in human cancer. Febs J. 2010; 277: 1118-1125. doi: 10.1111/j.1742-4658.2009.07463.x PMID: 19951354
16. Balasubramanian S, Hurley LH, Neidle S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov. 2011; 10: 261-275. doi: 10.1038/nrd3428 PMID: 21455236
17. Ohnmacht SA, Neidle S. Small-molecule quadruplex-targeted drug discovery. Bioorg Med Chem Lett. 2014; 24: 2602-2612. doi: 10.1016/j.bmcl.2014.04.029 PMID: 24814531
18. Collie GW, Parkinson GN. The application of DNA and RNA G-quadruplexes to therapeutic medicines. Chem Soc Rev. 2011; 40: 5867-5892. doi: 10.1039/c1cs15067g PMID: 21789296
19. Faudale M, Cogoi S, Xodo LE. Photoactivated cationic alkyl-substituted porphyrin binding to g4-RNA in the 5 ′-UTR of KRAS oncogene represses translation. Chem Commun. 2012; 48: 874-876. doi: 10.1039/c1cc15850c PMID: 22127206
20. Bugaut A, Balasubramanian S. 5′-UTR RNA G-quadruplexes: translation regulation and targeting. Nucleic Acids Res. 2012; 40: 4727-4741. doi: 10.1093/nar/gks068 PMID: 22351747
21. Lavrado J, Reszka AP, Moreira R, Neidle S, Paulo A. C-11 diamino cryptolepine derivatives NSC748392, NSC748393 and NSC748394: Anticancer profile and G-quadruplex stabilization. Bioorg Med Chem Lett. 2010; 20: 7042-7045. doi: 10.1016/j.bmcl.2010.09.110 PMID: 20952194
22. Lavrado J, Moreira R, Paulo A. Indoloquinolines as Scaffolds for Drug Discovery. Curr Med Chem. 2010; 17: 2348-2370. PMID: 20491639
23. Caprio V, Guyen B, Opoku-Boahen Y, Mann J, Gowan SM, Kelland LM et al. A novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline. Bioorg Med Chem Lett. 2000; 10: 2063-2066. PMID: 10999471
24. Ou TM, Lu YJ, Zhang C, Huang ZS, Wang XD, Tan JH, et al. Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives. J Med Chem. 2007; 50: 1465-1474. PMID: 17346034
25. Lavrado J, Borralho PM, Ohnmacht SA, Castro RE, Rodrigues CMP,Moreira R, et al. Synthesis, G-Quadruplex Stabilisation, Docking Studies, and Effect on Cancer Cells of Indolo[3,2-b]quinolines with One, Two, or Three Basic Side Chains. Chemmedchem. 2013; 8: 1648-1661. doi: 10.1002/cmdc.201300288 PMID: 23960016
26. Paramasivam M, Cogoi S, Xodo LE. Primer extension reactions as a tool to uncover folding motifs within complex G-rich sequences: analysis of the human KRAS NHE. Chem Commun (Camb). 2011; 47: 4965-4967. doi: 10.1039/c1cc10269a PMID: 21424008
27. Ohnmacht SA, Micco M, Petrucci V, Todd AK, Reszka AP, Gunaratnam M, et al. Sequences in the HSP90 promoter form G-quadruplex structures with selectivity for disubstituted phenyl bis-oxazole derivatives. Bioorg Med Chem Lett. 2012; 22: 5930-5935. doi: 10.1016/j.bmcl.2012.07.065 PMID: 22892119
28. Moore MJB, Schultes CM, Cuesta J, Cuenca F, Gunaratnam M, Tanious FA, et al. Trisubstituted acridines as G-quadruplex telomere targeting agents. Effects of extensions of the 3,6-and 9-side chains on quadruplex binding, telomerase activity, and cell proliferation. J Med Chem. 2006; 49: 582-599. PMID: 16420044
29. Collie GW, Promontorio R, Hampel SM, Micco M, Neidle S, Parkinson GN. Structural Basis for Telomeric G-Quadruplex Targeting by Naphthalene Diimide Ligands. JACS. 2012; 134: 2723-2731. doi: 10.1021/ja2102423 PMID: 22280460
30. Lebedeva IV, Su ZZ, Emdad L, Kolomeyer A, Sarkar D, Kitada S, et al. Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells. Oncogene. 2007; 26: 733-744. PMID: 16924242
31. Cogoi S, Zorzet S, Rapozzi V, Geci I, Pedersen EB, Xodo LE. MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice. Nucleic Acids Res. 2013; 41: 4049-4064. doi: 10.1093/nar/gkt127 PMID: 23471001
32. Wang JS, Chen Y, Ren JS, Zhao CQ, Qu XG. G-Quadruplex binding enantiomers show chiral selective interactions with human telomere. Nucleic Acids Res. 2014; 42: 3792-3802. doi: 10.1093/nar/gkt1354 PMID: 24413564
33. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol. 2009; 1: a001883. doi: 10.1101/cshperspect.a001883 PMID: 20066118
34. Borralho PM, Moreira da Silva IB, Aranha MM, Albuquerque C, Nobre Leitao C, Steer CJ, et al. Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53. Biochim Biophys Acta. 2007; 1772: 40-47. PMID: 17056233
35. Silva TF, Martins LM, Guedes da Silva MF, Fernandes AR, Silva A, Borralho PM, et al. Cobalt complexes bearing scorpionate ligands: synthesis, characterization, cytotoxicity and DNA cleavage. Dalton Trans. 2012; 41: 12888-12897. doi: 10.1039/c2dt11577h PMID: 22986733
36. Mansoor TA, Borralho PM, Dewanjee S, Mulhovo S, Rodrigues CM, Ferreira MJ. Monoterpene bisindole alkaloids, from the African medicinal plant Tabernaemontana elegans, induce apoptosis in HCT116 human colon carcinoma cells. J Ethnopharmacol. 2013; 149: 463-470. doi: 10.1016/j.jep.2013.06.051 PMID: 23872252